BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24358756)

  • 1. [Progress of research on genetic engineering antibody and its application in prevention and control of parasitic diseases].
    Yao Y; Yu CX
    Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi; 2013 Aug; 25(4):413-6. PubMed ID: 24358756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetically engineered antibodies: progress and prospects.
    Wright A; Shin SU; Morrison SL
    Crit Rev Immunol; 1992; 12(3-4):125-68. PubMed ID: 1476621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineered antibodies take center stage.
    Huston JS; George AJ
    Hum Antibodies; 2001; 10(3-4):127-42. PubMed ID: 11847424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent progress in biomolecular engineering.
    Ryu DD; Nam DH
    Biotechnol Prog; 2000; 16(1):2-16. PubMed ID: 10662483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody engineering: an overview.
    O'Kennedy R; Roben P
    Essays Biochem; 1991; 26():59-75. PubMed ID: 1778186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineered antibody approaches for Alzheimer's disease immunotherapy.
    Robert R; Wark KL
    Arch Biochem Biophys; 2012 Oct; 526(2):132-8. PubMed ID: 22475448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody engineering principles and applications.
    Loo L; Robinson MK; Adams GP
    Cancer J; 2008; 14(3):149-53. PubMed ID: 18536554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Progression and direction of humanized antibody research].
    Lin Y; Yan XY
    Sheng Wu Gong Cheng Xue Bao; 2004 Jan; 20(1):1-5. PubMed ID: 16108479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of genetic engineering on the pharmacokinetics of antibodies.
    Colcher D; Goel A; Pavlinkova G; Beresford G; Booth B; Batra SK
    Q J Nucl Med; 1999 Jun; 43(2):132-9. PubMed ID: 10429508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering Antibodies for the Treatment of Infectious Diseases.
    Fan G; Li J
    Adv Exp Med Biol; 2017; 1053():207-220. PubMed ID: 29549641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Research progress in gene engineered antibodies].
    Xiong SD; Wen BG; Li GW
    Sheng Li Ke Xue Jin Zhan; 2001 Jan; 32(1):23-6. PubMed ID: 12545772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering antibodies for clinical applications.
    Jain M; Kamal N; Batra SK
    Trends Biotechnol; 2007 Jul; 25(7):307-16. PubMed ID: 17512622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant polyclonal antibodies: the next generation of antibody therapeutics?
    Haurum JS
    Drug Discov Today; 2006 Jul; 11(13-14):655-60. PubMed ID: 16793535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant antibody libraries and selection technologies.
    Zhou H; Zhang YL; Lu G; Ji H; Rodi CP
    N Biotechnol; 2011 Sep; 28(5):448-52. PubMed ID: 21477669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Research advances of interleukin-15 in anti-parasitic infection].
    Li JY; Li ZY; Wang Y; Zhu XQ; Xu MJ
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2012 Jun; 30(3):196-200. PubMed ID: 23072135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease.
    Petkova SB; Akilesh S; Sproule TJ; Christianson GJ; Al Khabbaz H; Brown AC; Presta LG; Meng YG; Roopenian DC
    Int Immunol; 2006 Dec; 18(12):1759-69. PubMed ID: 17077181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current problems in the field of parasitic and tropical diseases].
    Savoia D
    G Batteriol Virol Immunol; 1977; 70(7-12):239-48. PubMed ID: 615749
    [No Abstract]   [Full Text] [Related]  

  • 18. [Research progress and prospects for vaccines against parasitic diseases].
    Liu SX; Cao JP
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2005 Oct; 23(5 Suppl):362-8, 373. PubMed ID: 16562469
    [No Abstract]   [Full Text] [Related]  

  • 19. Advances in parasite control through biotechnology.
    Zarlenga DS
    J Am Vet Med Assoc; 1994 May; 204(10):1616-21. PubMed ID: 8050941
    [No Abstract]   [Full Text] [Related]  

  • 20. A cost of disease resistance: paradigm or peculiarity?
    Brown JK
    Trends Genet; 2003 Dec; 19(12):667-71. PubMed ID: 14642742
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.